Table 1.
Characteristics of US adult patients who underwent melphalan base first auto PB MM transplant from 2008–2014 and reported with CIBMTR
| R-ISS I | R-ISS II | R-ISS III | |
|---|---|---|---|
| Number of patients | 199 | 360 | 69 |
| Number of centers | 55 | 64 | 33 |
| Median age at HCT (range) | 59 (41–76) | 60 (40–78) | 60 (43–75) |
| Male Gender | 115 (58) | 213 (59) | 41 (59) |
| Karnofsky score | |||
| 90–100 | 120 (60) | 198 (55) | 35 (51) |
| <90 | 73 (37) | 156 (43) | 29 (42) |
| Missing | 6 (3) | 6 (2) | 5 (7) |
| HCT-CI | |||
| 0 | 85 (43) | 108 (30) | 15 (22) |
| 1 | 28 (14) | 61 (17) | 9 (13) |
| 2 | 26 (13) | 66 (18) | 15 (22) |
| ≥3 | 60 (30) | 122 (33) | 30 (43) |
| Missing | 0 | 3 (<1) | 0 |
| Clinical Trial Enrollment | 76 (38) | 118 (33) | 18 (26) |
| LDH at diagnosis ≥ upper limit | 0 | 71 (20) | 58 (84) |
| ISS stage at diagnosis | |||
| Stage I | 199 | 45 (13) | 0 |
| Stage II | 0 | 214 (59) | 0 |
| Stage III | 0 | 101 (28) | 69 |
| Cytogenetic abnormality (conventional or FISH) | |||
| t(4;14)only | 0 | 16 (4) | 8 (12) |
| t(14; 16) only | 0 | 4 (1) | 3 (4) |
| Del17p only | 0 | 14 (4) | 4 (6) |
| 1q abnormality | 13 (7) | 25 (7) | 5 (7) |
| ≥ 2 High risk | 0 | 9 (3) | 5 (7) |
| No high risk Abnormality | 186 (93) | 292 (81) | 44 (64) |
| Lines of chemotherapy | |||
| 1 | 170 (85) | 289 (80) | 49 (71) |
| ≥2 | 29 (15) | 71 (20) | 20 (29) |
| Pre-transplant induction chemotherapy* | |||
| VTD | 15 (8) | 18 (5) | 5(7) |
| VRD | 89 (45) | 162 (45) | 31 (45) |
| VCD | 29 (15) | 59 (16) | 15 (22) |
| VD | 17 (9) | 37 (10) | 9 (13) |
| RD | 35 (18) | 68 (19) | 5 (7) |
| TD | 14 (7) | 16 (4) | 4 (6) |
| Disease status prior to HCT** | |||
| sCR/CR | 41 (21) | 70 (19) | 12 (17) |
| VGPR | 55 (28) | 122 (34) | 24 (35) |
| PR/SD/PD | 103 (52) | 168 (47) | 11 (48) |
| Melphalan dose (mg/m2) | |||
| 140 | 46 (23) | 89 (25) | 19 (28) |
| 200 | 153 (77) | 271 (75) | 50 (72) |
| Time from diagnosis to transplant | |||
| ≤ 6 months | 69 (35) | 139 (39) | 31 (45) |
| 6–12 months | 110 (55) | 172 (48) | 29 (42) |
| 12–18 months | 20 (10) | 49 (14) | 9 (13) |
| Year of transplant | |||
| 2008 | 44 (22) | 94 (26) | 11 (16) |
| 2009 | 17 (9) | 32 (9) | 6 (9) |
| 2010 | 8 (4) | 23 (6) | 10 (14) |
| 2011 | 30 (15) | 46 (13) | 6 (9) |
| 2012 | 39 (20) | 46 (13) | 8 (12) |
| 2013 | 30 (15) | 70 (19) | 9 (13) |
| 2014 | 31 (16) | 49 (14) | 19 (28) |
| Planned post-transplant treatment | 147 (74) | 245 (68) | 48 (70) |
| Median follow-up of survivors (range), months | 47 (6–97) | 48 (3–99) | 40 (12–97) |
*
Abbreviation: Bortezomib (V), Thalidomide (T), Dexamethasone (D), Lenalidomide (R), Cyclophosphamide (C)
**
Abbreviation: Stringent complete response (sCR), Complete response (CR), Very good partial response (VGPR), Partial response (PR), Stable disease (SD), Progressive disease (PD)